News

Represents the Company’s 29th product launch since inception in October 2023. Further strengthens Avenacy’s expanding portfolio of critical injectable medications. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Norepinephrine Bitartrate Injection, USP in the United States as a therapeutic generic equivalent for Levophed®, as approved...

Represents the Company’s 28th product launch since inception in October 2023. Marks expansion of Avenacy’s oncology portfolio, reflecting the Company’s ongoing commitment to supplying high-impact injectable medications. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bortezomib for Injection in the United States. The product contains...

Represents the Company’s 27th product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Tranexamic Acid in 0.7% Sodium Chloride Injection in the United States. The product contains the same active ingredient as CYKLOKAPRON®, as approved by the U.S. Food...

SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will attend DCAT Week from March 23-26, 2026 in New York City.

Represents the Company’s 26th product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced the launch of Diphenhydramine Hydrochloride Injection, USP in the United States. The product Is the generic equivalent of BENADRYL®, as approved by the U.S. Food and Drug Administration, and...

Achieved goal of launching 25 products by year-end 2025, with over 3 million units sold since January 2024 On track to achieve 200%+ FY2025 YoY revenue growth and 300%+ FY2025 YoY gross profit expansion Well-capitalized to continue executing on near-term critical injectable product launches while pursuing strategic portfolio expansion that supports the Company’s long-term growth...

SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will be attending the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026 in San Francisco, CA.

Company to highlight progress over the past year with existing and potential customers. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it will be attending the 2025 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition in Las Vegas, Nevada from December 7-10, 2025.

Company to discuss partnership opportunities at CPHI in Frankfurt, October 28th–30th. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will be attending CPHI Frankfurt 2025, taking place October 28th-30th.

Represents the Company’s 25th product launch since inception in October 2023. Marks the first Lidocaine product in Avenacy’s expanding portfolio. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced the launch of their first Lidocaine Hydrochloride Injection, USP in the United States. The product is a generic equivalent of...

Represents the Company’s 24th product launch since inception in October 2023. Unique 5-vial pack supports cost-effective inventory management for healthcare partners. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced the launch of Dehydrated Alcohol Injection, USP in the United States as a therapeutic generic equivalent of Ablysinol®, which ended...

New capital enables Avenacy to continue rapid growth and expand access to injectable medications. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company committed to supplying critical injectable medications to the U.S. market, today announced that it has entered into an Asset Based Lending (ABL) agreement with Texas Capital Bank. The agreement provides Avenacy with the financial...

24/7 Biopharma had the opportunity to speak with Jeffrey Yordon, CEO and co-founder of Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, at DCAT Week 2025. In this interview, Yordon discussed launching his latest company, how Avenacy aims to separate itself from competitors, and what it takes to navigate the tumultuous nature...

Represents the Company’s 23rd product launch since inception in October 2023. Expands Avenacy’s commercial reach into the mail order and retail pharmacy channels. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Leuprolide Acetate Injection in the United States. The product is a therapeutic generic equivalent...

Represents the Company’s 22nd product introduction since inception in October 2023 and 8th launch in 2025. Avenacy’s foundational portfolio of widely-used, critical injectable medications now includes six antibiotics. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Doxycycline for Injection, USP in the United States as a therapeutic...

Represents the Company’s 21st product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Propofol Injectable Emulsion, USP in the United States as a therapeutic generic equivalent for Diprivan® as approved by the U.S. Food and Drug Administration. Propofol Injectable Emulsion,...

Launches represent continued expansion of Avenacy’s foundational portfolio of widely-used, critical injectable medications. Portfolio now includes 20 products launched in less than 14 months since inception in October 2023. Company continues to make significant progress towards target of 25+ products by year-end 2025.

SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will be attending DCAT Week from March 17-20, 2025 in New York City.

Represents the Company’s fifteenth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in the United States as a therapeutic generic equivalent for Zometa® as approved by the U.S. Food and Drug Administration. Zoledronic Acid...

Launched 14 critical injectable medicines since Company inception in October 2023 and remains on track to meet target of 25+ products by year-end 2025. Pursuing two-pronged portfolio development strategy to establish strong foundation of critical injectable products while ensuring long-term competitiveness and return on investment. Company to attend the 43rd Annual J.P. Morgan Healthcare Conference....

SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will be attending the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025 in San Francisco, CA.

Company to highlight progress over the past year with potential customers and partners. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it will be attending the 2024 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition in New Orleans, Louisiana from December 8-12, 2024. At the...

Represents the Company’s fourteenth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Dexmedetomidine Injection, USP in the United States as a therapeutic generic equivalent for Precedex® as approved by the U.S. Food and Drug Administration. Dexmedetomidine Injection, USP...

JEFFERY YORDON Chief Executive Officer Avenacy Pharmaceutical companies play a critical role in ensuring that their medication packaging and labeling are designed to enhance accurate selection, product differentiation, understanding, and adherence in the home and healthcare facility setting with the ultimate goal of reducing the risk of errors and improving patient health outcomes. One of...

Successfully launched 13 products in less than one year. On track to reach goal of 25+ new product launches in first two years of company inception. Growing portfolio comprised of high-quality, FDA approved injectable medications to treat patients in acute care hospitals, outpatient clinics and physician offices. Strengthened leadership with addition of Dr. Patrick Soon-Shiong...

Represents the Company’s thirteenth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Metoclopramide Injection, USP in the United States as a therapeutic generic equivalent for Reglan® as approved by the U.S. Food and Drug Administration. Metoclopramide Injection, USP...

Dr. Patrick Soon-Shiong joins Jeff Yordon and Kam Phulwani to build injectable drug company following historical success of American Pharmaceutical Partners Company in strong financial position for significant growth and market expansion Dr. Patrick Soon-Shiong brings over 25 years of pharmaceutical industry experience, including successful commercialization of injectable generic drugs Investment made by NantCapital significantly...

Represents the Company’s twelfth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Palonosetron Hydrochloride Injection, USP in the United States as a therapeutic generic equivalent for Aloxi® as approved by the U.S. Food and Drug Administration. Palonosetron Hydrochloride Injection,...

Represents the Company’s eleventh product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Prochlorperazine Edisylate Injection, USP in the United States as a therapeutic generic equivalent for COMPAZINE® as approved by the U.S. Food and Drug Administration. Prochlorperazine Edisylate Injection,...

Represents the Company’s tenth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Tranexamic Acid Injection, USP in the United States as a therapeutic generic equivalent for Cyklokapron® as approved by the U.S. Food and Drug Administration. Tranexamic Acid Injection,...

Represents the Company’s ninth product launch since inception in October 2023. Avenacy to offer Isoproterenol Hydrochloride Injection, USP in the market-preferred vial presentation. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Isoproterenol Hydrochloride Injection, USP in the United States as a therapeutic generic equivalent for ISUPREL® as approved by...

Represents the Company’s eighth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Magnesium Sulfate in Water for Injection in the United States as approved by the U.S. Food and Drug Administration. Magnesium Sulfate in Water for Injection is...

SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Eptifibatide for Injection in the United States as a therapeutic equivalent generic for Integrilin® for Injection (Eptifibatide) approved by the U.S. Food and Drug Administration. Eptifibatide for Injection is indicated for use in acute coronary syndrome (ACS) and...

Sixth product launch in six months underscores Avenacy’s continued business momentum and commitment to providing essential medicines to patients. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Desmopressin Acetate for Injection in the United States as a therapeutic equivalent generic for DDAVP® for Injection (Desmopressin...

Furosemide represents the company’s fifth product launch and third product announced during DCAT Week 2024. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the United States as a therapeutic equivalent generic for Lasix® for Injection (furosemide) approved by the U.S. Food and...

Company adds two injectable products, Fosaprepitant for Injection and Fulvestrant Injection, to its growing portfolio for the U.S market. Latest progress marks continued momentum following October 2023 launch, with four portfolio products and a growing pipeline. Management to showcase the Company’s portfolio of critical injectable medications and differentiated business model at DCAT Week 2024 from...

Company’s second product to begin shipping to wholesale partners in January. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bivalirudin for Injection in the United States as a therapeutic equivalent generic for Angiomax® for Injection (bivalirudin) approved by the U.S. Food and Drug Administration. Bivalirudin...

Company’s first product to begin shipping to wholesale partners in January. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Melphalan Hydrochloride for Injection in the United States as a therapeutic equivalent generic for Alkeran® for Injection (melphalan hydrochloride) approved by the U.S. Food and Drug...

Company to exhibit and host meetings with potential customers and partners in preparation for initiating commercial operations by year-end 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it will be attending the 2023 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition in Anaheim, California...

Portfolio focused on high-quality FDA approved products to treat patients in acute care hospitals, outpatient clinics and physician offices; pursuing 25+ new products over next two years. Differentiated business model ensures supply chain resiliency through established manufacturing partner network. Seasoned team with proven track record of launching critical medications includes Jeffrey Yordon, CEO. Company to...